LRRK2 polyclonal, anti-human, mouse

Background:
Parkinson's disease is a disorder of movement, cognition and emotion. It is characterized pathologically by neuronal degeneration with Lewy bodies, which are cytoplasmic inclusion bodies containing deposits of aggregated proteins. Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) cause autosomal-dominant parkinsonism, with clinical features of Parkinson's disease and with pleomorphic pathology including deposits of aggregated protein. The LRRK2 protein consists of multiple domains and belongs to the Roco family, a novel group of the Ras/GTPase superfamily. Besides the GTPase (Roc) domain, it contains a predicted kinase domain, with homology to MAP kinase kinase kinases. LRRK2 is localized in the cytoplasm and is associated with cellular membrane structures. The purified LRRK2 protein demonstrates autokinase activity.

Alternative Name:
LRRK2, PARK8, augmented in rheumatoid arthritis 17, AURA17, Dardarin, Leucine rich repeat kinase 2, leucine rich repeat serine threonine protein kinase 2, Leucine-rich repeat serine/threonine-protein kinase 2, LRRK 2, LRRK2, LRRK2, PARK 8, PARK8, RIPK7, ROCO 2, ROCO2,

Application Dilution:
ICC:1:50-1:200
IHC:1:50-1:200

Specificity: LRRK2 polyclonal antibody detects endogenous levels of LRRK2 protein.

Immunogen:
Peptide.

MW: 286 kDa

Swiss-Prot: Q5S007(Human) Q5S006(Mouse)

Purification & Purity:
Peptide affinity purified.

Format:
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Storage:
Store at +4°C after thawing. Aliquot store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

For research use only, not for use in diagnostic procedure.